4.0
23. Dez. 2022
Mitarbeiter (anonym)
Aktueller Mitarbeiter
Empfehlen
CEO-Befürwortung
Geschäftsprognose
Pros
Company with a bright future and a strong pipeline of potentially innovative medicines. Gaining a strong foothold in the US market. Well funded and able to invest in the "next big thing".
Kontras
Inexperienced senior management not suited for taking the company to the next level although they are bringing in more seasoned management. Work Life Balance not great although it is improving through localizing much of the work and adding more resources.